The PODOMOUNT-Basket study investigates the safety and efficacy of BI 764198 in several rare kidney diseases associated with protein loss in the urine. The study aims to evaluate whether the treatment can reduce proteinuria and help preserve kidney function.
NEFRO-NL • Study portfolio for professionals
PODOMOUNT-Basket: BI 764198 in proteinuric kidney diseases
PODOMOUNT-Basket is a Phase II, multicentre, randomized, double-blind, placebo-controlled basket trial evaluating BI 764198 across several rare proteinuric kidney diseases that share common disease mechanisms. Participants are randomized in a 2:1 ratio to receive BI 764198 or placebo in addition to standard of care for 20 weeks.
Eligibility is assessed exclusively by the treating physician or study team.
To evaluate the safety and efficacy of BI 764198 in reducing proteinuria in patients with proteinuric kidney diseases, including sFSGS, treatment-resistant MCD, Alport syndrome, and treatment-resistant membranous nephropathy.
BI 764198 (TRPC6-inhibitor)
Randomized, placebo-controlled, quadruple-blind, parallel-group basket trial evaluating a therapeutic intervention.
20 weeks